Investorideas.com

Call 800 665 0411 to learn about our services for your stock

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS


 


investorideas.com - A Leading Global Investor Website for Biotech Industry Stocks

Investing in biotechnology stocks, pharma, medical technology and telemedicine has never been more exciting for investors with all of the new breakthroughs in technology and health. Let Investor Ideas help you find your next big idea in the sector with our free stock directories and news alerts. Don't miss out on the chance to invest in the future of healthcare and technology!

Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech Stocks

Investorideas Featured Company: Aethlon Medical, Inc. (NASDAQ: AEMD)

Aethlon Medical, Inc. (NASDAQ: AEMD) is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Get news alerts on this company!

Biotech News

Breaking Medical Technology News: Aethlon Medical (NASDAQ: AEMD) Receives Ethics Committee Approval for Hemopurifier Cancer Trial
SAN DIEGO - June 18, 2024 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that, on June, 13, 2024, the Human Research Ethics Committee (HREC) of the Central Adelaide Local Health Network (CALHN) granted full ethics approval for Aethlon's safety, feasibility and dose-finding clinical trial of the Hemopurifier in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda (pembrolizumab) or Opdivo (nivolumab).

Treatment of Blood Cancers - Stocks to watch (NYSE AMERICAN: ATNM) (NASDAQ: KURA), (NASDAQ: SYRS), (NASDAQ: SLS)
June 18, 2024 (Investorideas.com Newswire) Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases the second of a two-part series looking at developments for the treatment of blood cancers, including AML, featuring Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM).

Biopharma Stocks (NYSE American: ATNM) (NASDAQ: BPTH) (NASDAQ: STTK) (NASDAQ: MBRX) Quest for Solutions for Acute Myeloid Leukemia (AML)
June 17, 2024 (Investorideas.com Newswire) Investorideas.com, a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers.

Virus Treatments as Bird Flu Make Headlines (NASDAQ: AEMD) (NASDAQ: MRNA) (NASDAQ: IBRX) (NASDAQ: ALGS)
June 10, 2024 (Investorideas.com Newswire) Investorideas.com, a go-to investing platform, releases the second of a two-part series looking at news and developments for the treatment of viruses, featuring Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

The Hunt for Virus Treatments Continues Post Covid-19 (NASDAQ: AEMD) (NASDAQ: MRNA) (NASDAQ: IBRX) (NASDAQ: ALGS)
June 7, 2024 (Investorideas.com Newswire) Investorideas.com, a go-to investing platform, releases the second of a two-part series looking at news and developments for the treatment of viruses, featuring Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

Medical Technology Stocks in Play - SOBR Safe, Inc. (NASDAQ: SOBR) Gets Investors High on Stock Run
June 4, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to platform for big investing ideas including biotech and medical tech stocks , reports on trading for SOBR Safe, Inc. (NASDAQ:SOBR), a provider of next-generation transdermal alcohol detection solutions

Medical Device Stocks Setting New Standards (NASDAQ: AEMD) (NASDAQ: CTSO) (NASDAQ: CERS) (NYSE: BAX) (TSX: EDT)
June 4, 2024 (Investorideas.com Newswire) Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at medical device advancements for blood purification, featuring Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

Breaking Medical Technology News: Aethlon Medical (NASDAQ: AEMD) Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies
SAN DIEGO - June 3, 2024 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided the following update on its planned phase 1 safety, feasibility and dose-finding clinical trials of its Hemopurifier in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda or Opdivo.

Blood Purification Medical Devices Stocks in the News (NASDAQ: AEMD) (NASDAQ: CTSO) (NASDAQ: CERS) (NYSE: BAX) (TSX: EDT)
June 3, 2024 (Investorideas.com Newswire) Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at medical device advancements for blood purification, featuring Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

Biopharma stock Insmed (Nasdaq: INSM) doubles on Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis
May 28, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to platform for big investing ideas, reports on trading for Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases.

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Other Ideas - Guest Posts and / or sponsored financial content

Learn how to be published on our site: Buy a guest post on Investorideas.com

Biotech News from Newsfile

Therma Bright Completes Debt Settlements
Toronto, Ontario--(Newsfile Corp. - June 19, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, announces that further to its press release of May 22, 2024, it has now issued an aggregate of 19,250,000 common shares at a deemed price of $0.01 per share to settle aggregate debt of $192,500.All shares issued in relation to these debt...

Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2024 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 18, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, June 26, 2024 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2024. Medexus expects to file its financial statements and MD&A after markets close on June 25, 2024.To participate in the call, please dial the following numbers:888-506-0062 (toll-free) for Canadian...

Telo Genomics Announces Its TeloViewSMM Test Is Accepted as Laboratory Developed Test by CAP
Toronto, Ontario--(Newsfile Corp. - June 18, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that the College of American Pathologists (CAP) has recently accepted Telo Genomics' submission to add Telo's test for smoldering multiple myeloma (SMM), TeloViewSMM, as a...

PurMinds NeuroPharma Announces Its First Botanical Psilocybin Delivery to Bluestem API Inc.
Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - June 18, 2024) - PurMinds NeuroPharma ("PurMinds" or the "Company"), a neuro-medicine development company focused on advancing novel therapeutics for neurological and neurodegenerative disorders, today announced that it has signed the first Controlled Substances Supply Agreement with Bluestem API Inc ("Bluestem") to produce and supply botanical psilocybin from its Ontario based neurolab and production facility that holds a Dealer's...

Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging
Phio's Compound RXI-185 is designed to slow progression of UV induced collagen breakdownMarlborough, Massachusetts--(Newsfile Corp. - June 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, has been granted a skin care patent in South Korea.The patent, METHODS FOR TREATING AGING AND SKIN DISORDERS USING NUCLEIC ACIDS...

Subscribe to Biotech News